{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T06:56:17Z","timestamp":1793170577773,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004756","name":"Emil Aaltosen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004756","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007797","name":"Helsingin Yliopisto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007797","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006383","name":"Sy\u00f6p\u00e4j\u00e4rjest\u00f6t","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006383","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006196","name":"Oulun Yliopisto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.yexcr.2019.111508","type":"journal-article","created":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T11:00:25Z","timestamp":1564138825000},"page":"111508","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["In vitro humanized 3D microfluidic chip for testing personalized immunotherapeutics for head and neck cancer patients"],"prefix":"10.1016","volume":"383","author":[{"given":"Ahmed","family":"Al-Samadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedek","family":"Poor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Tuomainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ville","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aini","family":"Hyyti\u00e4inen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilida","family":"Suleymanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karri","family":"Mesimaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommy","family":"Wilkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antti","family":"M\u00e4kitie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4ivi","family":"Saavalainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuula","family":"Salo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexcr.2019.111508_bib1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1470-2045(13)70546-1","article-title":"Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study","volume":"15","author":"De Angelis","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.yexcr.2019.111508_bib2","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/MOO.0000000000000448","article-title":"Immunotherapy for recurrent\/metastatic head and neck cancer","volume":"26","author":"Alfieri","year":"2018","journal-title":"Curr. Opin. Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.yexcr.2019.111508_bib3","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexcr.2019.111508_bib4","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1634\/theoncologist.2016-0496","article-title":"FDA approval summary: pembrolizumab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy","volume":"22","author":"Larkins","year":"2017","journal-title":"The Oncologist"},{"key":"10.1016\/j.yexcr.2019.111508_bib5","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase Iphase Ib trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.yexcr.2019.111508_bib6","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.yexcr.2019.111508_bib7","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3389\/fonc.2018.00563","article-title":"Progresses and perspectives of anti-PD-1\/PD-L1 antibody therapy in head and neck cancers","volume":"28","author":"Yang","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.yexcr.2019.111508_bib8","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1186\/s12885-015-1944-z","article-title":"A novel human leiomyoma tissue derived matrix for cell culture studies","volume":"15","author":"Salo","year":"2015","journal-title":"BMC Canc."},{"issue":"1737","key":"10.1016\/j.yexcr.2019.111508_bib9","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2016.0482","article-title":"Organotypic three-dimensional assays based on human leiomyoma-derived matrices","volume":"373","author":"Salo","year":"2018","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.yexcr.2019.111508_bib10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1039\/C2LC40887B","article-title":"Cross talk between cancer and immune cells: exploring complex dynamics in a microfluidic environment","volume":"13","author":"Businaro","year":"2013","journal-title":"Lab Chip"},{"key":"10.1016\/j.yexcr.2019.111508_bib11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jid.2016.08.024","article-title":"Combining type I interferons and 5-aza-2'-deoxycitidine to improve anti-tumor response against melanoma","volume":"137","author":"Lucarini","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.yexcr.2019.111508_bib12","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41598-017-01013-x","article-title":"3D Microfluidic model for evaluating immunotherapy efficacy by tracking dendritic cell behaviour toward tumor cells","volume":"7","author":"Parlato","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.yexcr.2019.111508_bib13","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/jnr.23708","article-title":"Characterization of a new low-dose 6-hydroxydopamine model of Parkinson's disease in rat","volume":"94","author":"Penttinen","year":"2016","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.yexcr.2019.111508_bib14","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s12253-017-0270-y","article-title":"Immunohistochemical analysis of Foxp3+, CD4+, CD8+ cell infiltrates and PD\u2010L1 in oral squamous cell carcinoma","volume":"24","author":"Stasikowska\u2010Kanicka","year":"2018","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.yexcr.2019.111508_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.yexcr.2019.111508_bib16","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.oraloncology.2011.03.007","article-title":"Expression and prognostic impact of indoleamine 2,3-dioxygenase in oral squamous cell carcinomas","volume":"47","author":"Laimer","year":"2011","journal-title":"Oral Oncol."},{"key":"10.1016\/j.yexcr.2019.111508_bib17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40425-015-0094-9","article-title":"Targeting the indoleamine 2,3-dioxygenase pathway in cancer","volume":"3","author":"Moon","year":"2015","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.yexcr.2019.111508_bib18","doi-asserted-by":"crossref","first-page":"60123","DOI":"10.18632\/oncotarget.17768","article-title":"Crosstalk between tongue carcinoma cells, extracellular vesicles, and immune cells in in vitro and in vivo models","volume":"8","author":"Al-Samadi","year":"2017","journal-title":"Oncotarget"}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482719303507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482719303507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T04:27:55Z","timestamp":1757996875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014482719303507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0014482719303507"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2019.111508","relation":{},"ISSN":["0014-4827"],"issn-type":[{"value":"0014-4827","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro humanized 3D microfluidic chip for testing personalized immunotherapeutics for head and neck cancer patients","name":"articletitle","label":"Article Title"},{"value":"Experimental Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexcr.2019.111508","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111508"}}